Skip to main content
Journal cover image

Statin therapy and inflammation in patients with diabetes treated with high dose aspirin.

Publication ,  Journal Article
Chaudhary, R; Bliden, KP; Garg, J; Mohammed, N; Tantry, U; Mathew, D; Toth, PP; Franzese, C; Gesheff, M; Pandya, S; Gurbel, P
Published in: J Diabetes Complications
2016

BACKGROUND: Statin and aspirin form the therapeutic cornerstone in patients with coronary artery disease (CAD) and diabetes. Little is known about relationship of statins with blood thrombogenicity and inflammation in these patients. METHODS: Two hundred nine consecutive patients with diabetes and suspected CAD undergoing elective cardiac catheterization were divided in groups based on statin treatment in the Multi-Analyte, Thrombogenic, and Genetic Markers Atherosclerosis study. Urinary 11-dehydrothromboxane B2 (11-dh-TxB2), lipid profile and oxLDL/β2GPI were measured by AspirinWorks™ ELISA assay, vertical density gradient ultracentrifugation and immunoassay respectively. Thrombelastography, and ADP- and collagen-induced light transmittance aggregometry assessed thrombogenicity. CAD was classified as none/minor [<20% diameter stenosis (DS)], moderate (20-75% DS), or severe (>75% DS). RESULTS: Severe, moderate, and no CAD was observed in 66, 19, and 15% of patients respectively. Patients on statins had significantly lower 11-dh-TxB2, collagen-induced aggregation, total cholesterol, total LDL, LDL3, oxidized-LDL, Apo B100, and ApoB100/A1 ratio (p<0.01 for all). Statin therapy demonstrated a lower proportion of patients with high urinary 11-dh-TxB2 (>1500pg 11-dh-TxB2/mg creatinine) (25 vs. 57%, p=0.01). CONCLUSION: Statins along with aspirin, confers additional anti-inflammatory and antithrombotic effect in diabetics with CAD. Urinary 11-dh-TxB2 may be a useful biomarker for personalizing statin therapy.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Diabetes Complications

DOI

EISSN

1873-460X

Publication Date

2016

Volume

30

Issue

7

Start / End Page

1365 / 1370

Location

United States

Related Subject Headings

  • Thromboxane B2
  • Middle Aged
  • Male
  • Lipoproteins
  • Lipids
  • Inflammation
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • Fibrinolytic Agents
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chaudhary, R., Bliden, K. P., Garg, J., Mohammed, N., Tantry, U., Mathew, D., … Gurbel, P. (2016). Statin therapy and inflammation in patients with diabetes treated with high dose aspirin. J Diabetes Complications, 30(7), 1365–1370. https://doi.org/10.1016/j.jdiacomp.2016.05.002
Chaudhary, Rahul, Kevin P. Bliden, Jalaj Garg, Nafees Mohammed, Udaya Tantry, Denny Mathew, Peter P. Toth, et al. “Statin therapy and inflammation in patients with diabetes treated with high dose aspirin.J Diabetes Complications 30, no. 7 (2016): 1365–70. https://doi.org/10.1016/j.jdiacomp.2016.05.002.
Chaudhary R, Bliden KP, Garg J, Mohammed N, Tantry U, Mathew D, et al. Statin therapy and inflammation in patients with diabetes treated with high dose aspirin. J Diabetes Complications. 2016;30(7):1365–70.
Chaudhary, Rahul, et al. “Statin therapy and inflammation in patients with diabetes treated with high dose aspirin.J Diabetes Complications, vol. 30, no. 7, 2016, pp. 1365–70. Pubmed, doi:10.1016/j.jdiacomp.2016.05.002.
Chaudhary R, Bliden KP, Garg J, Mohammed N, Tantry U, Mathew D, Toth PP, Franzese C, Gesheff M, Pandya S, Gurbel P. Statin therapy and inflammation in patients with diabetes treated with high dose aspirin. J Diabetes Complications. 2016;30(7):1365–1370.
Journal cover image

Published In

J Diabetes Complications

DOI

EISSN

1873-460X

Publication Date

2016

Volume

30

Issue

7

Start / End Page

1365 / 1370

Location

United States

Related Subject Headings

  • Thromboxane B2
  • Middle Aged
  • Male
  • Lipoproteins
  • Lipids
  • Inflammation
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • Fibrinolytic Agents
  • Female